- Home
- GT vs DNLI Comparison
GT vs DNLI Comparison
Compare GT & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GT
- DNLI
- Stock Information
- Founded
- GT 1898
- DNLI 2013
- Country
- GT United States
- DNLI United States
- Employees
- GT N/A
- DNLI N/A
- Industry
- GT Automotive Aftermarket
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GT Consumer Discretionary
- DNLI Health Care
- Exchange
- GT Nasdaq
- DNLI Nasdaq
- Market Cap
- GT 2.0B
- DNLI 2.1B
- IPO Year
- GT N/A
- DNLI 2017
- Fundamental
- Price
- GT $7.58
- DNLI $14.96
- Analyst Decision
- GT Buy
- DNLI Strong Buy
- Analyst Count
- GT 4
- DNLI 13
- Target Price
- GT $11.38
- DNLI $32.64
- AVG Volume (30 Days)
- GT 9.3M
- DNLI 1.5M
- Earning Date
- GT 11-03-2025
- DNLI 11-06-2025
- Dividend Yield
- GT N/A
- DNLI N/A
- EPS Growth
- GT N/A
- DNLI N/A
- EPS
- GT N/A
- DNLI N/A
- Revenue
- GT $18,310,000,000.00
- DNLI N/A
- Revenue This Year
- GT N/A
- DNLI N/A
- Revenue Next Year
- GT $0.63
- DNLI $94,232.03
- P/E Ratio
- GT N/A
- DNLI N/A
- Revenue Growth
- GT N/A
- DNLI N/A
- 52 Week Low
- GT $6.51
- DNLI $10.57
- 52 Week High
- GT $12.03
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- GT 54.55
- DNLI 46.03
- Support Level
- GT $6.76
- DNLI $15.53
- Resistance Level
- GT $8.16
- DNLI $17.02
- Average True Range (ATR)
- GT 0.27
- DNLI 0.81
- MACD
- GT 0.13
- DNLI -0.25
- Stochastic Oscillator
- GT 58.21
- DNLI 35.63
About GT The Goodyear Tire & Rubber Company
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment. The company operates its business through three operating segments representing its regional tire businesses: Americas; Europe, the Middle East, and Africa (EMEA); and the Asia Pacific.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.